

FOR IMMEDIATE RELEASE – May 15, 2020

MindChild Medical, Inc. Announces Gates Funded UNC LABOR Study Selects Meridian™ Fetal ECG Research Device for Its Unparalleled Fetal ECG Capabilities

The Meridian Fetal Research Device Accurately Extracts Fetal ECG to Enable Analytics on Fetal ECG Morphology, Heart Rate, Heart Rate Variability and Uterine Activity Using Surface Electrodes

(North Andover, Massachusetts), MindChild Medical, Inc. today announced that the LABOR Study selected MindChild’s Meridian Fetal Research Device as the centerpiece of their study due to its unparalleled ability to accurately extract fetal ECG for advanced analytical research. Dr. Jeffrey Stringer, professor of obstetrics & gynecology in the UNC School of Medicine and LABOR Study Principal Investigator, stated that “of the nine companies evaluated, MindChild and their fetal research device is the only one that accurately produces the fetal ECG fidelity required for this study to succeed.” Dr. Jeffrey Stringer continued by stating “MindChild’s team and fetal ECG publications are world-class leading and far ahead of all their competitors.” Jay Ward, MindChild Medical’s Executive Vice President stated that “the Meridian Fetal monitoring technology was designed from the start to produce the best fetal ECG signal possible, opening the door to fetal diagnostics. Surrounding the fetus with thirty electrodes, 3-8 times more signals than our competitors, provides the necessary perspectives of the fetal heart that our advanced extraction algorithm needs to deliver such accurate waveforms.”

Each year some 300,000 women and 3 million babies worldwide die during childbirth or shortly thereafter, according to the World Health Organization. “In many parts of the world, the days surrounding childbirth are the riskiest period a mother and her newborn will ever face,” said Dr. Jeffrey Stringer. “These studies will develop resource-appropriate technologies to make that time much safer.”

About the LABOR Study

The Limiting Adverse Birth Outcomes in Resource-Limited Settings (LABOR) study, funded by a \$14 million grant from the Bill & Melinda Gates Foundation to the University of North Carolina, will focus on the period of pregnancy between the onset of labor through delivery. It will evaluate 15,000 women at high-volume clinical sites in three developing countries. The team will provide wearable physiologic sensors to monitor laboring mothers and their fetuses and carefully document their clinical course and birth outcomes.

Using participant data recorded and produced by the Meridian M110R Fetal Research Device, researchers will develop new algorithms that can both identify individual women’s risk of specific adverse outcomes and help predict and plan for the specific interventions women will likely need. These precision approaches can lead to earlier intervention and better health outcomes for mothers and newborns.

About the Meridian Non-Invasive Fetal ECG Research Device

The Meridian M110R Fetal Research Device is an external fetal monitor using abdominal surface electrodes that measures and records electrophysiological signals of the mother and fetus. In real-time, Meridian also extracts and records the fetal ECG waveform, fetal and maternal heart rate, fetal and maternal R-R interval, uterine muscle contraction signal, and processing statistics including fetal and maternal ECG signal quality.

MindChild Medical, Inc.
1600 Osgood Street
Suite 2017
N. Andover, MA 01845
T: 978.975.1160
www.mindchild.com



MERIDIAN M110R Fetal Research Device is designed for women who are ≥ 24 completed weeks, with singleton pregnancies, using surface electrodes on the maternal abdomen. MERIDIAN is intended for use by healthcare professionals in a clinical setting.

About MindChild Medical, Inc.

MindChild Medical, Inc., is a privately funded medical device company founded in 2008. MindChild's principal technology platform, the Meridian non-invasive fetal electrocardiograph (ECG) monitor, is designed to report fetal heart rate data equivalent to the gold standard fetal scalp electrode in addition to novel ECG metrics intended to provide obstetricians a deeper understanding of fetal/maternal health and management.

MindChild was co-founded by Adam Wolfberg, MD, Assistant Professor, Tufts Medical Center, Gari Clifford, PhD, previously Principal Research Scientist at Harvard-MIT Division of Health and Science Technology (currently Interim Chair, Associate Professor, Biomedical Informatics (Emory University)), James Robertson, President and CEO, and Jay Ward, Executive Vice President, both of E-TROLZ, Inc. MindChild has exclusively licensed intellectual property from the Massachusetts Institute of Technology, Tufts Medical Center and E-TROLZ, Inc., a Massachusetts technology company that develops and commercializes breakthrough physiologic monitoring platforms for a wide variety of applications. For more information, please visit www.mindchild.com.

Contacts

MindChild Medical, Inc.
Jay Ward, 978-975-1160 x113
EVP
jay.ward@mindchild.com